ORIENT EUROPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.2 TWD | +2.30% |
|
+3.43% | +8.48% |
| Sales 2022 | 4.73B 145M 11.61B | Sales 2023 | 4.59B 141M 11.27B | Capitalization | 3.37B 104M 8.28B |
|---|---|---|---|---|---|
| Net income 2022 | -311M -9.55M -763M | Net income 2023 | 144M 4.42M 354M | EV / Sales 2022 | 1.33 x |
| Net Debt 2022 | 3.15B 96.77M 7.74B | Net Debt 2023 | 2.74B 84.08M 6.72B | EV / Sales 2023 | 1.33 x |
| P/E ratio 2022 |
-10.1
x | P/E ratio 2023 |
23.4
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
2.57% | Free-Float | 35.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.30% | ||
| 1 week | +3.43% | ||
| Current month | -2.99% | ||
| 1 month | -3.10% | ||
| 3 months | +11.35% | ||
| 6 months | +5.50% | ||
| Current year | +8.48% |
1 week
40.50
42.85
1 month
40.3045.80
Current year
36.7045.80
1 year
35.6548.30
3 years
32.1048.30
5 years
32.1065.80
10 years
32.10104.00
| Managers | Title | Age | Since |
|---|---|---|---|
Cheng Hung Tsai
CHM | Chairman | - | - |
Anita Chen
IRC | Investor Relations Contact | - | - |
I Hsin Chang
AUD | Comptroller/Controller/Auditor | - | 31/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Praveen Tyle
BRD | Director/Board Member | 64 | 31/12/02 |
Cheng Hung Tsai
CHM | Chairman | - | - |
Hwa-Min Lin
BRD | Director/Board Member | - | 29/06/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 42.2 | +2.30% | 67,353 |
| 25/04/24 | 41.25 | -0.96% | 32,266 |
| 24/04/24 | 41.65 | +1.46% | 126,700 |
| 23/04/24 | 41.05 | +1.36% | 38,643 |
| 22/04/24 | 40.5 | -0.74% | 137,096 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.
Sector
Food Processing
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.48% | 112M | |
| +8.20% | 7.78B | |
| +0.34% | 7.38B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- 4120 Stock
